Prediction of trastuzumab-induced cardiotoxicity using transthoracic echocardiography and cardiac biomarkers in patients with gastric cancer

Prediction of trastuzumab-induced cardiotoxicity using transthoracic echocardiography and cardiac biomarkers in patients with gastric cancer - Prediction of trastuzumab-induced cardiotoxicity using transthoracic echocardiography and cardiac biomarkers in patients with gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030429

Enrollment

Registered

2017-12-16

Start date

2017-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer therapeutics-related cardiac dysfunction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction Patients who receive trastuzumab plus chemotherapy (pyrimidine fluoride drug plus cisplatin) or chemotherapy alone No previous chemotherapy within 6 months Prospect of life prognosis more than 3 months Men or women older than 20 years of age Written informed consent can be obtained

Exclusion criteria

Exclusion criteria: The investigator's consider unsuitable for registration Suitable echocardiographic data can not be obtained for diagnostic imaging Patients can not have clinical examinations due to bad general condition Patients can not visit the hospital periodically

Design outcomes

Primary

Measure	Time frame
Changes of left ventricular ejection fraction value before and after chemotherapy	—

Countries

Japan

Contacts

Public ContactAtai WATANABE

Cancer Institute Hospital Department of General Medicine

atai.watanabe@jfcr.or.jp03-3520-0111

Outcome results